Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
Gilead Sciences (GILD) has announced it will release its first quarter 2025 financial results on Thursday, April 24, 2025, after market close. The company's management will host a webcast at 4:30 p.m. Eastern Time to discuss the quarterly results and provide a business update.
The live webcast will be accessible through the Investors section of Gilead's website and will remain archived there for one year. The biopharmaceutical company, headquartered in Foster City, California, operates in more than 35 countries and focuses on developing innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer.
Gilead Sciences (GILD) ha annunciato che rilascerà i suoi risultati finanziari del primo trimestre 2025 giovedì 24 aprile 2025, dopo la chiusura del mercato. La direzione dell'azienda ospiterà un webcast alle 16:30 ora orientale per discutere i risultati trimestrali e fornire un aggiornamento sull'attività.
Il webcast dal vivo sarà accessibile attraverso la sezione Investitori del sito web di Gilead e rimarrà archiviato lì per un anno. L'azienda biofarmaceutica, con sede a Foster City, California, opera in oltre 35 paesi e si concentra sullo sviluppo di farmaci innovativi per malattie potenzialmente letali, tra cui HIV, epatite virale, COVID-19 e cancro.
Gilead Sciences (GILD) ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el jueves 24 de abril de 2025, después del cierre del mercado. La dirección de la empresa llevará a cabo un webcast a las 4:30 p.m. hora del Este para discutir los resultados trimestrales y proporcionar una actualización empresarial.
El webcast en vivo será accesible a través de la sección de Inversores del sitio web de Gilead y permanecerá archivado allí durante un año. La empresa biofarmacéutica, con sede en Foster City, California, opera en más de 35 países y se centra en el desarrollo de medicamentos innovadores para enfermedades potencialmente mortales, incluyendo VIH, hepatitis viral, COVID-19 y cáncer.
길리어드 사이언스(GILD)는 2025년 1분기 재무 결과를 2025년 4월 24일 목요일, 시장 마감 후 발표할 것이라고 발표했습니다. 회사 경영진은 동부 표준시 기준 오후 4시 30분에 분기 결과를 논의하고 사업 업데이트를 제공하는 웹캐스트를 주최할 것입니다.
실시간 웹캐스트는 길리어드 웹사이트의 투자자 섹션을 통해 접근할 수 있으며, 1년 동안 그곳에 보관됩니다. 캘리포니아 포스터 시티에 본사를 둔 이 생명공학 회사는 35개국 이상에서 운영되며, HIV, 바이러스성 간염, COVID-19 및 암 등 생명을 위협하는 질병을 위한 혁신적인 약물 개발에 집중하고 있습니다.
Gilead Sciences (GILD) a annoncé qu'il publiera ses résultats financiers du premier trimestre 2025 le jeudi 24 avril 2025, après la fermeture du marché. La direction de l'entreprise animera un webinaire à 16h30, heure de l'Est, pour discuter des résultats trimestriels et fournir une mise à jour sur l'activité.
Le webinaire en direct sera accessible via la section Investisseurs du site web de Gilead et y restera archivé pendant un an. L'entreprise biopharmaceutique, dont le siège est à Foster City, en Californie, opère dans plus de 35 pays et se concentre sur le développement de médicaments innovants pour des maladies potentiellement mortelles, notamment le VIH, l'hépatite virale, le COVID-19 et le cancer.
Gilead Sciences (GILD) hat angekündigt, dass es am Donnerstag, den 24. April 2025, nach Börsenschluss seine Finanzergebnisse für das erste Quartal 2025 veröffentlichen wird. Das Management des Unternehmens wird um 16:30 Uhr Eastern Time ein Webcast veranstalten, um die Quartalsergebnisse zu besprechen und ein Geschäftsupdate zu geben.
Der Live-Webcast wird über den Bereich Investoren auf der Website von Gilead zugänglich sein und dort ein Jahr lang archiviert bleiben. Das biopharmazeutische Unternehmen mit Hauptsitz in Foster City, Kalifornien, ist in mehr als 35 Ländern tätig und konzentriert sich auf die Entwicklung innovativer Medikamente gegen lebensbedrohliche Krankheiten wie HIV, Virushepatitis, COVID-19 und Krebs.
- None.
- None.
A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250410465777/en/
Jacquie Ross, CFA – Investors
investor_relations@gilead.com
Source: Gilead Sciences, Inc.
FAQ
When will Gilead Sciences (GILD) report Q1 2025 earnings?
How can investors access GILD's Q1 2025 earnings call?
How long will GILD's Q1 2025 earnings webcast be available?
What therapeutic areas does Gilead Sciences (GILD) focus on?
